 |
|
JAMA-EXPRESS
Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial
Gregg W. Stone, MD;
Stephen G. Ellis, MD;
Charles D. O’Shaughnessy, MD;
Steven L. Martin, MD;
Lowell Satler, MD;
Thomas McGarry, MD;
Mark A. Turco, MD;
Dean J. Kereiakes, MD;
Lynne Kelley, MD;
Jeffrey J. Popma, MD;
Mary E. Russell, MD; for the TAXUS V ISR Investigators
JAMA. 2006;295:1253-1263. Published online March 12, 2006 (doi:10.1001/jama.295.11.1253).
Context Restenosis within bare-metal stents is often treated with repeat percutaneous coronary intervention, although subsequent recurrence rates are high, with vascular brachytherapy (VBT) affording the best results. The effectiveness of drug-eluting stents in this setting has not been established.
Objective To investigate the safety and efficacy of the polymer-based, slow-release paclitaxel-eluting stent in patients with restenotic lesions after prior stent implantation in native coronary arteries.
Design, Setting, and Patients Prospective, multicenter, randomized trial conducted between June 6, 2003, and July 16, 2004, at 37 North American academic and community-based institutions in 396 patients with in-stent restenosis of a previously implanted bare-metal coronary stent (vessel diameter, 2.5-3.75 mm; lesion length,  46 mm).
Interventions Patients were randomly assigned to undergo angioplasty followed by VBT with a  source (n = 201) or paclitaxel-eluting stent implantation (n = 195). Clinical and angiographic follow-up at 9 months was scheduled in all patients.
Main Outcome Measure Ischemia-driven target vessel revascularization at 9 months.
Results Diabetes mellitus was present in 139 patients (35.1%). Median reference vessel diameter was 2.65 mm and median lesion length was 15.3 mm. In the VBT group, new stents were implanted in 22 patients (10.9%) and in the paclitaxel-eluting stent group, multiple stents were required in 57 patients (29.2%), with median stent length of 24 mm. Follow-up at 9 months was complete in 194 patients in the VBT group and 191 patients in the paclitaxel-eluting stent group (96.5% and 97.9%, respectively). For VBT and paclitaxel-eluting stents, respectively, the number of events and 9-month rates for ischemic target lesion revascularization were 27 (13.9%) vs 12 (6.3%) (relative risk [RR], 0.45; 95% confidence interval [CI], 0.24-0.86; P = .01); for ischemic target vessel revascularization, 34 (17.5%) vs 20 (10.5%) (RR, 0.60; 95% CI, 0.36-1.00; P = .046); and for overall major adverse cardiac events, 39 (20.1%) vs 22 (11.5%) (RR, 0.57; 95% CI, 0.35-0.93; P = .02), with similar rates of cardiac death or myocardial infarction (10 [5.2%] vs 7 [3.7%]; RR, 0.71; 95% CI, 0.28-1.83; P = .48) and target vessel thrombosis (5 [2.6%] vs 3 [1.6%]; RR, 0.61; 95% CI, 0.15-2.50; P = .72). Angiographic restenosis at 9 months was 31.2% (53 of 170 patients) with VBT and 14.5% (25 of 172 patients) with paclitaxel-eluting stents (RR, 0.47; 95% CI, 0.30-0.71; P<.001).
Conclusion Treatment of bare-metal in-stent restenotic lesions with paclitaxel-eluting stents rather than angioplasty followed by VBT reduces clinical and angiographic restenosis at 9 months and improves event-free survival.
Trial Registration ClinicalTrials.gov Identifier: NCT00287573
Author Affiliations: Department of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (Dr Stone); Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Ellis); Department of Cardiology, Elyria Memorial Hospital, Elyria, Ohio (Dr O’Shaughnessy); Department of Cardiology, Nebraska Heart Institute, Lincoln (Dr Martin); Department of Cardiology, Washington Hospital Center, Washington, DC (Dr Satler); Department of Cardiology, Oklahoma Heart Institute, Oklahoma City (Dr McGarry); Department of Cardiology, Washington Adventist Hospital, Takoma Park, Md (Dr Turco); Department of Cardiology, Christ Hospital, Cincinnati, Ohio (Dr Kereiakes); Boston Scientific Corp, Natick, Mass (Drs Kelley and Russell); and Department of Cardiology, Brigham and Women's Hospital, Boston, Mass (Dr Popma).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTERS
Paclitaxel-Eluting Stents, Brachytherapy, and In-Stent Restenosis
Hideaki Kaneda and Junya Ako
JAMA. 2006;296(15):1838.
EXTRACT
| FULL TEXT
Paclitaxel-Eluting Stents, Brachytherapy, and In-Stent Restenosis—Reply
Gregg W. Stone, Jeffrey J. Popma, and Stephen G. Ellis
JAMA. 2006;296(15):1838-1839.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The SISR Randomized Trial
David R. Holmes, Jr, Paul Teirstein, Lowell Satler, Michael Sketch, James O’Malley, Jeffery J. Popma, Richard E. Kuntz, Peter J. Fitzgerald, Hong Wang, Eileen Caramanica, Sidney A. Cohen, and for the SISR Investigators
JAMA. 2006;295(11):1264-1273.
ABSTRACT
| FULL TEXT
Brachytherapy for In-Stent Restenosis: A Distant Second Choice to Drug-Eluting Stent Placement
Debabrata Mukherjee and David J. Moliterno
JAMA. 2006;295(11):1307-1309.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis: Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study
Alfonso et al.
J Am Coll Cardiol 2008;52:1621-1627.
ABSTRACT
| FULL TEXT
The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis
Habara et al.
Heart 2008;94:1162-1165.
ABSTRACT
| FULL TEXT
Catheter-Based Treatment of Coronary Artery Disease: Past, Present, and Future
Holmes and Williams
Circ Cardiovasc Intervent 2008;1:60-73.
ABSTRACT
| FULL TEXT
Optimal treatment for in-stent restenosis after BMS--DES, coated balloon, or scalpel?
Mukherjee
Eur Heart J 2008;29:1595-1596.
FULL TEXT
Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial
Ellis et al.
Eur Heart J 2008;29:1625-1634.
ABSTRACT
| FULL TEXT
Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents: Insights From Serial Intravascular Ultrasound Analyses in the TAXUS-V and -VI Trials
Aoki et al.
J Am Coll Cardiol Intv 2008;1:161-167.
ABSTRACT
| FULL TEXT
Off-label use of drug-eluting stents putting it in perspective.
Grines
J Am Coll Cardiol 2008;51:615-617.
FULL TEXT
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:172-209.
FULL TEXT
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
King et al.
Circulation 2008;117:261-295.
FULL TEXT
Drug-eluting stents: effective and safe for every patient and every lesion?
Zeymer and Zahn
Eur Heart J 2007;28:2559-2560.
FULL TEXT
Drug-Eluting Stent Update 2007: Part II: Unsettled Issues
Daemen and Serruys
Circulation 2007;116:961-968.
FULL TEXT
Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment
Airoldi et al.
Circulation 2007;116:745-754.
ABSTRACT
| FULL TEXT
The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2007;50:270-285.
FULL TEXT
Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation
Torella et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;292:H2935-H2943.
ABSTRACT
| FULL TEXT
Recurrent angina after coronary revascularization: a clinical challenge
Abbate et al.
Eur Heart J 2007;28:1057-1065.
ABSTRACT
| FULL TEXT
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri et al.
NEJM 2007;356:1020-1029.
ABSTRACT
| FULL TEXT
Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis: Meta-Analysis of Randomized Trials
Dibra et al.
J Am Coll Cardiol 2007;49:616-623.
ABSTRACT
| FULL TEXT
Long-Term Outcomes After Management of Restenosis or Thrombosis of Drug-Eluting Stents
Mishkel et al.
J Am Coll Cardiol 2007;49:181-184.
ABSTRACT
| FULL TEXT
Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry
Williams et al.
Circulation 2006;114:2154-2162.
ABSTRACT
| FULL TEXT
Paclitaxel-eluting stents, brachytherapy, and in-stent restenosis.
Kaneda and Ako
JAMA 2006;296:1838-1838.
FULL TEXT
i2 Innovation in Intervention Summit
Knopf
J Am Coll Cardiol 2006;47:D9-D12.
FULL TEXT
JournalScan
Malik
Heart 2006;92:862-864.
FULL TEXT
Drug-Eluting Stents vs. Brachytherapy for Bare-Metal In-Stent Restenosis
Journal Watch Cardiology 2006;2006:1-1.
FULL TEXT
Brachytherapy for In-Stent Restenosis: A Distant Second Choice to Drug-Eluting Stent Placement
Mukherjee and Moliterno
JAMA 2006;295:1307-1309.
FULL TEXT
|
